CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation

New England Journal of Medicine

Volumn 369, Issue 13, 2013, Pages 1227-1236

  Marty, Francisco M ^a   Winston, Drew J ^b   Rowley, Scott D ^c   Vance, Estil ^d   Papanicolaou, Genovefa A ^e   Mullane, Kathleen M ^f   Brundage, Thomas M ^g   Robertson, Alice T ^g   Godkin, Susan ^g   Momméja Marin, Hervé ^g   Boeckh, Michael ^h  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^g Chimerix   (United States)

^h Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; PLACEBO; VIRUS DNA;

ABDOMINAL PAIN; ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ANTIVIRAL ACTIVITY; ANXIETY; ARTICLE; BONE MARROW SUPPRESSION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EYE TOXICITY; FATIGUE; FEVER; GASTROESOPHAGEAL REFLUX; GRAFT RECIPIENT; HUMAN; INFECTION PREVENTION; INSOMNIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PERIPHERAL EDEMA; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STAPHYLOCOCCAL BACTEREMIA; THROMBOCYTOPENIA; THRUSH; VOMITING;

EID: 84884528238     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1303688     Document Type: Article

References (32)

1. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003;9:543-58. (Pubitemid 38351787)
2. Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 2011; 11:284-92. [Erratum, Lancet Infect Dis 2011; 11:343.]
3. Green ML, Leisenring W, Stachel D, et al. Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012;18:1687-99.
4. Marty FM, Bryar J, Browne SK, et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 2007;110:490-500. (Pubitemid 47105386)
5. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004;103:2003-8. (Pubitemid 38326213)
6. Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009;113:5711-9.
7. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993;118:173-8. (Pubitemid 23034801)
8. Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: results of a placebo-controlled, double-blind trial. Ann Intern Med 1993;118:179-84. (Pubitemid 23034802)
9. Hostetler KY. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res 2009;82:A84-98.
10. Aldern KA, Ciesla SL, Winegarden KL, Hostetler KY. Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C] cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol Pharmacol 2003;63:678-81. (Pubitemid 36297340)
11. Painter W, Robertson A, Trost LC, Godkin S, Lampert B, Painter G. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Antimicrob Agents Chemother 2012;56:2726-34.
12. Ciesla SL, Trahan J, Wan WB, et al. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res 2003;59:163-71. (Pubitemid 36966748)
13. Kern ER, Hartline C, Harden E, et al. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob Agents Chemother 2002;46:991-5. (Pubitemid 34260341)
14. Painter GR, Hostetler KY. Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. Trends Biotechnol 2004;22:423-7. (Pubitemid 38993227)
15. Quenelle DC, Lampert B, Collins DJ, Rice TL, Painter GR, Kern ER. Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies. J Infect Dis 2010;202:1492-9.
16. Williams-Aziz SL, Hartline CB, Harden EA, et al. Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob Agents Chemother 2005;49:3724-33. (Pubitemid 41233024)
17. Randhawa P, Zemlicka J, Sauerbrei A, et al. Anti-BK virus activity of nucleoside analogs. Antimicrob Agents Chemother 2008;52:1519-21. (Pubitemid 351522024)
18. Randhawa P, Farasati NA, Shapiro R, Hostetler KY. Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro. Antimicrob Agents Chemother 2006;50:1564-6.
19. Rinaldo CH, Gosert R, Bernhoff E, Finstad S, Hirsch HH. 1-O-hexadecyloxypropyl cidofovir (CMX001) effectively inhibits polyomavirus BK replication in primary human renal tubular epithelial cells. Antimicrob Agents Chemother 2010;54:4714-22.
20. Hartline CB, Gustin KM, Wan WB, et al. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J Infect Dis 2005;191:396-9. (Pubitemid 40139765)
21. Quenelle DC, Collins DJ, Herrod BP, et al. Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice. Antimicrob Agents Chemother 2007;51:3940-7. (Pubitemid 350057792)
22. Rice AD, Adams MM, Lampert B, et al. Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans. Viruses 2011;3:63-82.
23. Beadle JR, Hartline C, Aldern KA, et al. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob Agents Chemother 2002;46:2381-6. (Pubitemid 34793439)
24. Kern ER, Collins DJ, Wan WB, Beadle JR, Hostetler KY, Quenelle DC. Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. Antimicrob Agents Chemother 2004;48:3516-22. (Pubitemid 39129353)
25. Bidanset DJ, Beadle JR, Wan WB, Hostetler KY, Kern ER. Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection. J Infect Dis 2004;190:499-503. (Pubitemid 38982087)
26. Florescu DF, Pergam SA, Neely MN, et al. Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Biol Blood Marrow Transplant 2012;18:731-8.
27. Paolino K, Sande J, Perez E, et al. Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001. J Clin Virol 2011;50:167-70.
28. Common Terminology Criteria for Adverse Events. v4.0 (CTCAE). Bethesda, MD: National Cancer Institute, 2010 (NIH publication no. 09-5410) (http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5x11. pdf).
29. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825-8.
30. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002;34:1094-7. (Pubitemid 34289682)
31. Smith IL, Cherrington JM, Jiles RE, Fuller MD, Freeman WR, Spector SA. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis 1997;176:69-77. [Erratum, J Infect Dis 1998;177:1140-1.] (Pubitemid 27272853)
32. Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010;23:689-712.